Fadi Shawket

Artiklar

Article: ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY. 2026
Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing-Remitting MS
Shawket F; Lycke J; Salzer J; Piehl F; Fink K; Lange N; Mellergård J; Malmeström C; Sundström P; Erngren I; al‐Grety A; Freyhult E; Kultima K; Burman J; Svenningsson A
Article: LANCET NEUROLOGY. 2022;21(8):693-703
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Al Nimer F; Sundstrom P; Gunnarsson M; Johansson R; Mellergard J; Rosenstein I; Ayad A; Sjoblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J

Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2025;31(3):697-698
Dimethyl fumarate treatment in multiple sclerosis is associated with a decrease in serum glial fibrillary acidic protein Results from the RIFUND-MS trial
Shawket F; Lycke J; Salzer J; Piehl F; Fink K; Mellergard J; Malmestrom C; Sundstrom P; Lange N; Erngren I; Al-Grety A; Kultima K; Freyhult E; Burman J; Svenningsson A